A5075077546- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Neuroblastoma Research and Treatments
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- Cancer, Hypoxia, and Metabolism
- Adrenal and Paraganglionic Tumors
- Gallbladder and Bile Duct Disorders
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- MRI in cancer diagnosis
- Virus-based gene therapy research
- Sarcoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Cancer Diagnosis and Treatment
- Lymphatic Disorders and Treatments
- Glioma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Moffitt Cancer Center
2016-2025
University of South Florida
2015-2021
University of Tampa
2020
Hospital of the University of Pennsylvania
2004-2012
University of Pennsylvania
2007-2008
Philadelphia University
2008
Children's Hospital of Philadelphia
2008
Biomedical Research Foundation of Northwest Louisiana
2007-2008
Imaging Center
2007
Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients advanced, progressive, somatostatin-receptor–positive tumors.
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic cancer. Lutetium-177 (177Lu)–PSMA-617 a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review literature on in neuroendocrine tumors (NETs) different primary origin, discuss issues
LBA4 Background: Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC lesions. 177 Lu-PSMA-617 a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and surrounding microenvironment. Method: VISION was an international, randomized, open-label phase III study evaluating men with PSMA-positive previously treated...
High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neoplasms. Because their rarity, there is an overall lack prospectively collected data available to advise practitioners as how best manage these patients. As result, practices largely based on expert opinion. Recently, distinction was made between well-differentiated high-grade (G3) tumors poorly differentiated carcinomas, with this, pathologic details, appropriate imaging treatment have...
Although radiation-induced mesenteritis or peritonitis can potentially exacerbate the risk of bowel obstruction, there are no data in literature on incidence intestinal obstruction related to peptide receptor radionuclide therapy. Methods: The records all patients treated with 177Lu-DOTATATE at Moffitt Cancer Center between April 2018 and October 2019 were evaluated. number who developed within 3 mo a treatment was divided by total preexisting peritoneal mesenteric disease. Management...
Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine tumors (NETs) has not been well characterized using PET imaging. Understanding the degree and uniformity of SSTR is important to establish role SSTR-targeted treatments NETs. <b>Methods:</b> A retrospective institutional review patients with NETs who underwent DOTATATE imaging from March 2017 February 2023 was performed. <b>Results:</b> In total, 48 <sup>68</sup>Ga- or <sup>64</sup>Cu-DOTATATE were identified. Four had...
New effective therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with median survival of less than 1 y. The melanocortin receptor (MC1R) is expressed in 94% melanoma metastases, and MC1R-specific ligand (MC1RL) high affinity selectivity MC1R was previously developed. <b>Methods:</b> <sup>225</sup>Ac-DOTA-MC1RL conjugate synthesized radiochemical yield purity tested vitro biostability cytotoxicity cells, the lanthanum-DOTA-MC1RL analog binding...
5001 Background: In the phase 3 VISION trial, targeted radioligand therapy with lutetium ( 177 Lu) vipivotide tetraxetan ([ Lu]Lu-PSMA-617; Lu-PSMA-617) significantly prolonged radiographic progression-free survival (rPFS) and overall (OS) when added to standard of care (SoC) in patients advanced prostate-specific membrane antigen (PSMA) PET-positive metastatic castration-resistant prostate cancer. Benefits were consistent across most pre-specified subgroups. this post hoc exploratory...
Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to receptors are used for palliation hormonal syndromes control tumor growth. The long-acting SSAs octreotide release lanreotide commonly in the first-line metastatic setting because their tolerable side effect profile. Radiolabeled both imaging treatment NETs. <sup>177</sup>Lu-DOTATATE is a β-emitting radiolabeled SSA that has...